BridgeBio Discloses 13,805,126 BBOT Shares and Vested Options
Rhea-AI Filing Summary
BridgeBio Pharma LLC and its parent BridgeBio Pharma, Inc. reported an initial Form 3 disclosing 13,805,126 shares of common stock of BridgeBio Oncology Therapeutics, Inc. (BBOT) held indirectly. The filing shows two fully vested stock options covering 63,934 and 9,494 shares with exercise prices of $3.83 and $1.02, respectively. Voting and investment power is exercised by the parent, and the filers disclaim individual beneficial ownership except for any pecuniary interest.
Positive
- Material indirect stake disclosed: 13,805,126 shares reported, showing clear ownership position in BBOT
- Options fully vested: 63,934 and 9,494 optioned shares are fully vested, enabling potential future exercise
Negative
- Indirect ownership structure: Voting and investment power is exercised by the parent entity, limiting clarity on individual director control
- Disclaimers of beneficial ownership: The reporting parties disclaim beneficial ownership except for pecuniary interest, which may reduce certainty about active control
Insights
TL;DR: Significant indirect stake disclosed; no new transactions or changes to liquidity reported.
The Form 3 documents a sizable indirect stake of 13.8 million shares in BBOT, which is material in absolute terms but the filing does not state percentage ownership or any transfers. The inclusion of two fully vested options signals potential future share issuance if exercised, at exercise prices of $3.83 and $1.02. Because the filing is an initial ownership disclosure rather than a transaction report, its immediate market impact is likely limited.
TL;DR: Control is exercised at the parent level and directors disclaim individual ownership.
The report clarifies that voting and investment power over the reported shares is exercised by BridgeBio Pharma, Inc., and that the board members listed disclaim beneficial ownership except for pecuniary interests. That structure is important for governance transparency, confirming indirect ownership and centralized control rather than individual director control over voting rights.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Shares are held by BridgeBio Pharma LLC ("BBIO LLC"). Voting and investment power over the shares held by BBIO LLC is exercised by its parent entity, BridgeBio Pharma, Inc. ("BBIO"). The board of directors of BBIO consists of Neil Kumar, Ph.D., Eric Aguiar, M.D., Jennifer E. Cook, Douglas A. Dachille, Ronald J. Daniels, Andrea J. Ellis, Fred Hassan, Charles Homcy, M.D., Andrew W. Lo, Ph.D., Frank P. McCormick, Ph.D., F.R.S., D.Sc., James C. Momtazee, Ali J. Satvat, Randal W. Scott, Ph.D., and Hannah A. Valantine, M.D. (each a BBIO director, and collective, the BBIO Directors"). None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such shares. Each of BBIO and the BBIO Directors disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its, his, or her pecuniary interest therein, if any. (Continued from Footnote 1) This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The shares subject to such option are fully vested.
